11.82USD+11.40%Mkt Cap: 526.72M USDP/E: —Last update: 2026-05-22
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. I…
Industry Peers
Medical Devices152.25BUSDP/E 24.5
85.88BUSDP/E 24.2
53.45BSEKP/E 22.7
53.33BSEKP/E 98.9
52.13BDKKP/E 22.1
38.61BEURP/E 18.3
23.15BSEK—
22.25BEURP/E 23.4
loading…
Indicators:|
Key Statistics
Company
Market Cap526.72M USD
Enterprise Value280.19M USD
Revenue (TTM)110.24M USD
Gross Profit55.54M USD
Net Income (TTM)-73.20M USD
Revenue/Share2.508 USD
Last Price11.82 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees420
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.44
PEG—
EV/EBITDA-3.71
EV/Revenue2.54
P/S4.29
P/B1.74
EPS (TTM)-1.37
EPS (Forward)-2.39
52W Range
8.80013% of range32.71
52W High32.71 USD
52W Low8.800 USD
Profitability
Gross Margin55.40%
Oper. Margin-87.86%
EBITDA Margin-68.45%
Profit Margin-73.02%
ROE-25.45%
ROA-22.27%
Growth
Revenue Growth56.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.92M USD
CapEx (TTM)5.30M USD
FCF Margin-39.96%
FCF Yield-8.36%
Net Debt-192.61M USD
Net Debt/EBITDA2.55
Balance Sheet
Debt/Equity0.03
Current Ratio10.69
Quick Ratio9.38
Book Value/Sh6.087 USD
Cash/Share4.477 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)19.18 USD
Target Range11.00 USD – 32.00 USD
# Analysts11
Ownership
Shares Out.44.56M
Float25.37M
Insiders0.97%
Institutions112.61%
Short Interest
Short Ratio5.1d
Short % Float13.97%
Short % Out.13.90%
Shares Short6.19M
Short (prev mo.)7.60M
Technical
SMA 5010.56 (+11.9%)
SMA 20018.79 (-37.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)970.71K
Avg Vol (10d)727.73K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—